Bone Mineral Density, Childhood Cancer Survivors
Conditions
Keywords
Bone mineral density, Childhood cancer survivors
Brief summary
This research study is evaluating bone mineral density in childhood cancer survivors who have a history of bone fracture.
Detailed description
The purpose of this research study is to learn more about the status of bones in children and young-adults who have had bone fractures after treatment for childhood cancer. Bone complications including fracture can be important issues for some childhood cancer survivors. In this study we are measuring bone mineral density in children and young adults who have had bone fracture after treatment for childhood cancer. We will measure bone mineral density in two ways. We will use: 1) dual energy x-ray absorptiometry (also known as DXA), and 2) peripheral quantitative computed tomography (also known as pQCT).
Interventions
Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
Subjects will undergo pQCT assessment of radius and tibia.
Sponsors
Dana-Farber Cancer Institute
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
8 Years to 20 Years
Healthy volunteers
No
Inclusion criteria
* History of childhood cancer * Age ≥ 8 years and \< 20 years at time of enrollment * ≥ 2 years since completion of cancer-directed therapy for first cancer * Received chemotherapy for treatment of childhood cancer * History of bone fracture after the conclusion of chemotherapy\* * Not currently receiving cancer-directed therapy * Signed written informed consent (by parent if patient is \< 18 years of age, or by patient, if he or she is ≥18 years of age) * Patient assent for those ≥10 years of age and \< 18 years of age for whom a parent provides informed consent (\*History of bone fracture will be based on patient/parent report of fracture occurrence and will be confirmed in review of the medical record whenever feasible.)
Exclusion criteria
* Current treatment with bisphosphonates (as of time of enrollment) * Current treatment with the anticonvulsant depakote (at time of enrollment) * Currently pregnant
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total body BMD (total body less head) and lumbar spine BMD | Participants to undergo a single baseline assessment on day 1; to be measured at ≥ 2 years since completion of cancer-directed therapy | DXA assessment (z-score) |
| Volumetric BMD of distal radius | Participants to undergo a single baseline assessment on day 1; to be measured at ≥ 2 years since completion of cancer-directed therapy | pQCT assessment |
Secondary
| Measure | Time frame |
|---|---|
| 25-hydroxy vitamin D level | Participants to undergo a single baseline assessment on day 1; to be measured at ≥ 2 years since completion of cancer-directed therapy |
Countries
United States
Outcome results
None listed